Centre for Infection and Immunity Lille Director Camille Locht announced on Thursday that the results of Phase 1 clinical trials of an intranasal pertussis vaccine were published in the online medical journal PLOS ONE.
Researchers from the CHILD-INNOVAC European project and 10 partners tested the efficacy and safety of the vaccine, and conducted clinical trials in humans.
Locht said pertussis is a "forgotten" disease that affects tens of millions. Approximately 300,000 children die annually from the disease, which is caused by Bordetella pertussis and respiratory syncytial virus.
The test took place in Sweden, where a large portion of the population has not received a pertussis vaccine. During the trials, all adverse events, such as cough, sneezing, nasal discharge and effects on general health, were recorded. The colonization of the nasal mucosa was also recorded, as well as triggering of an immune response.
"It is of special interest that a single nasal administration was able to induce an immune response that was maintained for at least 6 months, i.e. for the duration of the study," Locht said.
Researchers were able to apply the vaccine in three dosage levels. The next stage of trials will include administering the vaccine in a higher dose to increase the level of colonization of the nasal mucosa. Locht and his collaborators said that they will work to improve the stability of the vaccine over time to prepare for industrial development in the future.